Clinical Trial: Probiotic Treatment of Acute Distal Ulcerative Colitis with Rectally Administered Escherichia Coli Nissle 1917 (EcN)

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2010 Apr 20

PMID 20398311

Citations 89

Authors

Harald Matthes

Thomas Krummenerl

Manfred Giensch

Corinna Wolff

Jurgen Schulze

Affiliations

Soon will be listed here.

Abstract

Background: Probiotics are effective in inflammatory bowel diseases. Clinical effectiveness and dose dependency of E. coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC).

Methods: In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to treatment with either 40, 20, or 10 ml enemas (N = 24, 23, 23) containing 10E8 EcN/ml or placebo (N = 20). The study medication was taken once daily for at least 2 weeks. After 2, 4 and/or 8 weeks the clinical DAI was assessed together with tolerance to treatment. Patients who reached clinical DAI <or= 2 within that time were regarded as responders.

Results: According to ITT analysis the number of responders was not significantly higher in the EcN group than in the placebo group (p = 0.4430, 2-sided). However, the Jonckheere-Terpstra rank correlation for dose-dependent efficacy indicated a significant correlation of per-protocol responder rates (p = 0.0446, 2-sided). Time to remission was shortest with EcN 40 ml, followed by EcN 20 ml. The number of adverse events did not differ notably.

Conclusion: In contrast to ITT analysis, efficacy of rectal EcN application was significant in PP and points to EcN as a well tolerated treatment alternative in moderate distal UC.

Trial Registration: German Clinical Trials Register DRK00000234.

Citing Articles

Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.

Farah A, Paul P, Khan A, Sarkar A, Laws S, Chaari A Front Med (Lausanne). 2025; 12:1435030.

PMID: 40041456 PMC: 11876558. DOI: 10.3389/fmed.2025.1435030.

Recent Advances in Gut Microbiome Modulation: Effect of Probiotics, Prebiotics, Synbiotics, and Postbiotics in Inflammatory Bowel Disease Prevention and Treatment.

Saedi S, Derakhshan S, Hasani A, Khoshbaten M, Poortahmasebi V, Milani P Curr Microbiol. 2024; 82(1):12.

PMID: 39589525 DOI: 10.1007/s00284-024-03997-y.

Modulation of gut microbiome in response to the combination of Nissle 1917 and sugars: a pilot study using host-free system reflecting impact on interpersonal microbiome.

Heer K, Kaur M, Sidhu D, Dey P, Raychaudhuri S Front Nutr. 2024; 11:1452784.

PMID: 39502876 PMC: 11534610. DOI: 10.3389/fnut.2024.1452784.

Evaluating the Therapeutic Efficacy of Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances.

Rezaei S, Ghorbani E, Al-Asady A, Avan A, Soleimanpour S, Khazaei M Curr Pharm Des. 2024; 31(6):413-421.

PMID: 39385420 DOI: 10.2174/0113816128322653240925115114.

Engineering a Novel Probiotic Toolkit in for Sensing and Mitigating Gut Inflammatory Diseases.

Weibel N, Curcio M, Schreiber A, Arriaga G, Mausy M, Mehdy J ACS Synth Biol. 2024; 13(8):2376-2390.

PMID: 39115381 PMC: 11334186. DOI: 10.1021/acssynbio.4c00036.

References

Bohm S, Kruis W . [Probiotics in chronic inflammatory bowel disease]. MMW Fortschr Med. 2006; 148(35-36):30-4. View

Guslandi M, Giollo P, Testoni P . A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003; 15(6):697-8. DOI: 10.1097/00042737-200306000-00017. View

Collins P, Rhodes J . Ulcerative colitis: diagnosis and management. BMJ. 2006; 333(7563):340-3. PMC: 1539087. DOI: 10.1136/bmj.333.7563.340. View

TRUELOVE S, Richards W . Biopsy studies in ulcerative colitis. Br Med J. 1956; 1(4979):1315-8. PMC: 1980058. DOI: 10.1136/bmj.1.4979.1315. View

Rembacken B, Snelling A, Hawkey P, Chalmers D, Axon A . Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999; 354(9179):635-9. DOI: 10.1016/s0140-6736(98)06343-0. View

Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P . Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999; 13(8):1103-8. DOI: 10.1046/j.1365-2036.1999.00560.x. View

Sutherland L, Martin F, Greer S, Robinson M, Greenberger N, Saibil F . 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92(6):1894-8. DOI: 10.1016/0016-5085(87)90621-4. View

Higgins P, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann E . Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005; 54(6):782-8. PMC: 1774553. DOI: 10.1136/gut.2004.056358. View

Quigley E . Probiotics in the management of colonic disorders. Curr Gastroenterol Rep. 2007; 9(5):434-40. DOI: 10.1007/s11894-007-0055-7. View

10.

Hanauer S . Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998; 4(2):79-83. DOI: 10.1002/ibd.3780040202. View

11.

Uslu N, Demir H, Saltik-Temizel I, Topaloglu R, Gurakan F, Yuce A . Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci. 2007; 52(11):2926-9. DOI: 10.1007/s10620-006-9586-2. View

12.

Blum-Oehler G, Oswald S, Eiteljorge K, Sonnenborn U, Schulze J, Kruis W . Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol. 2003; 154(1):59-66. DOI: 10.1016/s0923-2508(02)00007-4. View

13.

Furuta R, Kusugami K, Goto H . [Enema therapy for ulcerative colitis patients]. Nihon Rinsho. 2005; 63(5):845-9. View

14.

Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997; 11(5):853-8. DOI: 10.1046/j.1365-2036.1997.00225.x. View

15.

Seksik P, Dray X, Sokol H, Marteau P . Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. Mol Nutr Food Res. 2008; 52(8):906-12. DOI: 10.1002/mnfr.200700147. View

16.

Frandsen N, Saugmann S, Marcussen N . Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron. 2002; 92(1):200-2. DOI: 10.1159/000064461. View

17.

Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C . NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. 2004; 72(10):5750-8. PMC: 517557. DOI: 10.1128/IAI.72.10.5750-5758.2004. View

18.

van Bodegraven A, Mulder C . Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?. World J Gastroenterol. 2006; 12(38):6115-23. PMC: 4088103. DOI: 10.3748/wjg.v12.i38.6115. View

19.

Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J . Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol. 2004; 186(16):5432-41. PMC: 490877. DOI: 10.1128/JB.186.16.5432-5441.2004. View

20.

NISSLE A . [Mutaflor and its medical significance]. Z Klin Med. 1951; 2(3-4):68. View